OncoMatch/Clinical Trials/NCT06717750
A Study of CSCJC3456 in Patients With Advanced Malignant Tumors
Is NCT06717750 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies CSCJC3456 tablet for advanced malignant solid tumors.
Treatment: CSCJC3456 tablet — This study is a multicenter, open phase I clinical study of dose escalation, cohort expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of CSCJC3456 in patients with advanced malignant solid tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Biomarker criteria
Allowed: FGFR4 positivity
Cohort A (hepatocellular carcinoma, including at least 2 participants with FGFR4 positivity)
Allowed: FGFR1 positivity
Cohort B (colorectal cancer, including at least 2 participants with FGFR1 or FGFR2 positivity)
Allowed: FGFR2 positivity
Cohort B (colorectal cancer, including at least 2 participants with FGFR1 or FGFR2 positivity)
Allowed: FGFR1 positivity
Cohort C (gastric cancer (including adenocarcinoma at the gastroesophageal junction), including at least 2 participants with FGFR1 or FGFR2 positivity)
Allowed: FGFR2 positivity
Cohort C (gastric cancer (including adenocarcinoma at the gastroesophageal junction), including at least 2 participants with FGFR1 or FGFR2 positivity)
Allowed: FGFR2 positivity
Cohort D (recurrent/metastatic endometrial cancer, including at least 2 participants with FGFR2 or FGFR3 positivity)
Allowed: FGFR3 positivity
Cohort D (recurrent/metastatic endometrial cancer, including at least 2 participants with FGFR2 or FGFR3 positivity)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: fgfr inhibitor (pemetrexed, erdafilone, infigranib, forodesine, ponatinib, dovitinib, nintedanib, azd4547, nvp-bgj398, ly2784455, bay1163877)
Lab requirements
Blood counts
Kidney function
Liver function
Adequate Organ and bone marrow function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify